WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 405650

CAS#: 208260-29-1

Description: ZM336372 is a Raf-1 activating agent, has been shown to cause growth inhibition and suppression of hormone secretion in a neuroendocrine cell line. ZM336372 causes growth inhibition, suppression of hormone secretion, and up-regulation of cell cycle inhibitors in a human hepatocellular carcinoma cell line, similar to that previously seen in NETs.

Price and Availability


USD 90
USD 450
USD 2650

USD 150
USD 750
USD 3850

USD 250
USD 1450
USD 6450

ZM336372, purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 405650
Name: ZM336372
CAS#: 208260-29-1
Chemical Formula: C23H23N3O3
Exact Mass: 389.17394
Molecular Weight: 389.45
Elemental Analysis: C, 70.93; H, 5.95; N, 10.79; O, 12.32

Synonym: ZM336372 ZM-336372; ZM 336372

IUPAC/Chemical Name: 3-(Dimethylamino)- N -[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]benzamide


InChi Code: InChI=1S/C23H23N3O3/c1-15-7-10-18(24-23(29)17-5-4-6-19(13-17)26(2)3)14-21(15)25-22(28)16-8-11-20(27)12-9-16/h4-14,27H,1-3H3,(H,24,29)(H,25,28)

SMILES Code: O=C(NC1=CC=C(C)C(NC(C2=CC=C(O)C=C2)=O)=C1)C3=CC=CC(N(C)C)=C3

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1: Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. Epub 2010 Nov 9. PubMed PMID: 21062976.

2: Burgess S, Echeverria V. Raf inhibitors as therapeutic agents against neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):120-7. Review. PubMed PMID: 20201822.

3: Deming D, Geiger P, Chen H, Kunnimalaiyaan M, Holen K. ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines. J Surg Res. 2010 Jun 1;161(1):28-32. Epub 2009 Jul 12. PubMed PMID: 20031160; PubMed Central PMCID: PMC3379885.

4: Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009 Dec;50(6):1861-70. PubMed PMID: 19821497; PubMed Central PMCID: PMC2891152.

5: Echeverria V, Burgess S, Gamble-George J, Arendash GW, Citron BA. Raf inhibition protects cortical cells against beta-amyloid toxicity. Neurosci Lett. 2008 Oct 17;444(1):92-6. Epub 2008 Aug 8. PubMed PMID: 18706973.

6: Deming D, Geiger P, Chen H, Vaccaro A, Kunnimalaiyaan M, Holen K. ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line. J Gastrointest Surg. 2008 May;12(5):852-7. PubMed PMID: 18299943.

7: Kunnimalaiyaan M, Ndiaye M, Chen H. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery. 2007 Dec;142(6):959-64; discussion 959-64. PubMed PMID: 18063082; PubMed Central PMCID: PMC2180346.

8: Houben R, Ortmann S, Schrama D, Herold MJ, Berberich I, Reichardt HM, Becker JC. Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol. 2007 Sep;127(9):2116-22. Epub 2007 May 3. PubMed PMID: 17476292.

9: Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. 2007 Feb 8;26(6):813-21. Epub 2006 Aug 7. PubMed PMID: 16909118.

10: Lai KP, Mak NK, Wei X, Wong RN, Wong MH, Wong CK. Bifunctional modulating effects of an indigo dimer (bisindigotin) to CYP1A1 induction in H4IIE cells. Toxicology. 2006 Sep 21;226(2-3):188-96. Epub 2006 Jul 4. PubMed PMID: 16901605.